perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2020-65-5-139-144perinatology-1249Research ArticleК XVII РОССИЙСКОМУ КОНГРЕССУ «ПЕДИАТРИЯ И ДЕТСКАЯ ХИРУРГИЯ В ПРИВОЛЖСКОМ ФЕДЕРАЛЬНОМ ОКРУГЕ». ОБЗОРЫ ЛИТЕРАТУРЫTO THE XVI RUSSIAN CONGRESS «PEDIATRICS AND PEDIATRIC SURGERY IN THE PRIVOLZHSKY FEDERAL DISTRICT». LITERATURE REVIEWПрименение статинов при семейной гиперхолестеринемии у детейUse of statins in children with familial hypercholesterolemiahttps://orcid.org/0000-0002-6662-3548СадыковаД. И.SadykovaD. I.

Садыкова Динара Ильгизаровна — доктор медицинских наук, заведующий кафедрой госпитальной педиатрии.

420012 Казань, ул. Бутлерова, д. 49

https://orcid.org/0000-0001-7115-0186ШкольниковаМ. А.ShkolnikovaM. A.

Школьникова Мария Александровна — доктор медицинских наук, профессор, научный руководитель.

125412 Москва, ул. Талдомская, д. 2

Moscow

ГалимоваЛ. Ф.GalimovaL. F.

Галимова Лилия Фаридовна — кандидат медицинских наук, врач ДРКБ, ассистент кафедры госпитальной педиатрии Казанского ГМУ

ORCID: 0000-0001-5576-5279

lilu1@inbox.ruhttps://orcid.org/0000-0002-1732-7443СластниковаЕ. С.SlastnikovaE. S.

Сластникова Евгения Сергеевна — врач Детской республиканской клинической больницы, аспирант кафедры госпитальной педиатрии.

420138 Казань, Оренбургский тракт, д. 140

ФГБОУ ВО Казанский государственный медицинский университетРоссияKazan State Medical UniversityRussian FederationОСП Научно-исследовательский клинический институт педиатрии им. академика Ю.Е. Вельтищева, ФГАОУ ВО РНИМУ им. Н.И. ПироговаРоссияVeltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical UniversityRussian FederationФГБОУ ВО Казанский государственный медицинский университет; ГАУЗ Детская республиканская клиническая больница Минздрава Республики ТатарстанРоссияKazan State Medical University; Republican Children's Clinical HospitalRussian Federation202021112020655139144Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20202020Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/1249

Семейная гиперхолестеринемия — самое распространенное генетическое заболевание в мире. Характеризуется повышением в организме уровня общего холестерина и липопротеинов низкой плотности с детства. Оптимальными признаны диагностика и начало терапии заболевания в детском возрасте до появления осложнений, таких как аортальный стеноз, атеросклеротические изменения стенок артерий. Для лечения в качестве препаратов первой линии рекомендованы статины. Однако ввиду немногочисленного опыта мнения среди клиницистов относительно возраста начала липидснижающей терапии различаются. В настоящем обзоре предпринята попытка критически изучить имеющиеся данные мировой литературы, касающиеся применения статинов у детей с семейной гиперхолестеринемией, их эффективности и безопасности.

Familial hypercholesterolemia Is the most common genetic disease in the world. It is characterized by an increase in the level of total cholesterol and low-density lipoproteins since childhood. It is desired to diagnose and start treatment in childhood prior to development of complications, such as aortic stenosis, atherosclerotic changes in the artery walls. Statins are recommended as the first-line medications. However, due to limited experience, the clinicians have different opinions regarding the age of initiation of hypolipidemic therapy. The article is aimed to critically examine the data on the use of statins in children with familial hypercholesterolemia, their effectiveness and safety available in the world literature.

детисемейная гиперхолестеринемияобщий холестеринлипопротеины низкой плотностилечениеста-тиныэффективностьпобочное действиеchildrenfamilial hypercholesterolemiatotal cholesterollow density lipoproteinstreatmentstatinsefficacyside effectsReferences. Mathers C.D., Iburg B.K., Fat M.D., Shibuya K., Inoue M., Stein C. et al. Global Burden of Disease in 2002: data sources, methods and results. Global Programme on Evidence for Health Policy Discussion Paper No. 54 World Health Organization December 2003. https://www.who.int/healthinfo/pa-per54.pdf.Mathers C.D., Iburg B.K., Fat M.D., Shibuya K., Inoue M., Stein C. et al. Global Burden of Disease in 2002: data sources, methods and results. Global Programme on Evidence for Health Policy Discussion Paper No. 54 World Health Organization December 2003. https://www.who.int/healthinfo/pa-per54.pdf.Weiss L.A., Pan L., Abney M., Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nature Genetics 2006; 38(2): 218-222. DOI: 10.1038/ng1726Weiss L.A., Pan L., Abney M., Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nature Genetics 2006; 38(2): 218-222. DOI: 10.1038/ng1726Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Gold-berger Z.D., Hahn E.J. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140(11): e596—e646. DOI: 10.1161/CIR.0000000000000678Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Gold-berger Z.D., Hahn E.J. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140(11): e596—e646. DOI: 10.1161/CIR.0000000000000678Ежов М.В., Близнюк С.А., Тмоян Н.А. Рожкова Т.А., Ду-пляков Д.В., Сальченко В.А. и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов оченьвысокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС). Российский кардиологический журнал 2019; 5: 7—13. DOI: 10.15829/1560-4071-2019-5-7-13Yezhov M.V., Bliznyuk S.A., Tmoy-an N.A. Rozhkova T.A., Duplyakov D.V., Salchenko V.A. et al. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Rossiiskii kar-diologicheskii zhurnal (Russian Journal of Cardiology) 2019; 5: 7-13. (in Russ.) DOI: 10.15829/1560-4071-2019-5-7-13Классификация и эффекты статинов. [Электронный ресурс]. https://noatero.ru/ru/klassifikaciya-i-effekty-statinovClassification and effects of statins. [Electronic resource]. https://noatero.ru/ru/klassifikaciya-i-effekty-statinov (in Russ.)Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckerd E. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-2472. DOI:10.1093/eurheartj/ehx144Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckerd E. et al. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-2472. DOI:10.1093/eurheartj/ehx144Grundy S.M., Arai H, Barter P., Bersot T.P., Betteridge D.J., Carmena R. et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia — full report. J Clin Lipidol 2014; 8: 29-60. DOI: 10.1016/j.jacl.2013.12.005Grundy S.M., Arai H, Barter P., Bersot T.P., Betteridge D.J., Carmena R. et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia — full report. J Clin Lipidol 2014; 8: 29-60. DOI: 10.1016/j.jacl.2013.12.005Luirink I.K., Wiegman A., Kusters D.M., Hof M.H., Groothoff J.W., de Groot E. et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. New Engl J Med 2019; 381(16): 1547—1556. DOI: 10.1056/nejmoa1816454Luirink I.K., Wiegman A., Kusters D.M., Hof M.H., Groothoff J.W., de Groot E. et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. New Engl J Med 2019; 381(16): 1547—1556. DOI: 10.1056/nejmoa1816454Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425—2437. DOI: 10.1093/eurheartj/ehv157Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425—2437. DOI: 10.1093/eurheartj/ehv157Clauss S.B., Holmes K.W., Hopkins P., Stein E., Cho M., Tate A.C. et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005; 116: 682—688. DOI: 10.1542/peds.2004-2090Clauss S.B., Holmes K.W., Hopkins P., Stein E., Cho M., Tate A.C. et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005; 116: 682—688. DOI: 10.1542/peds.2004-2090Wiegman A., Hutten B.A., de Groot E., Rodenburg J., Bac-cer H., Buller H. R. et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2014; 292: 331—337. DOI: 10.1001/jama.292.3.331Wiegman A., Hutten B.A., de Groot E., Rodenburg J., Bac-cer H., Buller H. R. et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2014; 292: 331—337. DOI: 10.1001/jama.292.3.331Mamann N., Lemale J., Karsenty A., Dubern B., Girardet J.-P., Tounian P. Intermediate-Term Efficacy and Tolerance of Statins in Children. J Pediatr 2019; 210: 161—165. DOI: 10.1016/j.jpeds.2019.03.032Mamann N., Lemale J., Karsenty A., Dubern B., Girardet J.-P., Tounian P. Intermediate-Term Efficacy and Tolerance of Statins in Children. J Pediatr 2019; 210: 161—165. DOI: 10.1016/j.jpeds.2019.03.032McCrindle B.W., Ose L., Marais A.D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2013; 142: 74—80. DOI: 10.1016/j.accreview.2003.09.056McCrindle B.W., Ose L., Marais A.D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2013; 142: 74—80. DOI: 10.1016/j.accreview.2003.09.056Vuorio A., Kuoppala J., Kovanen P.T., Humphries S.E., Tons-tad S., Wiegman A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Syst Rev 2019; 11: CD006401. DOI: 10.1002/14651858.cd006401.pub5Vuorio A., Kuoppala J., Kovanen P.T., Humphries S.E., Tons-tad S., Wiegman A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Syst Rev 2019; 11: CD006401. DOI: 10.1002/14651858.cd006401.pub5Avis H.J., Hutten B.A., Gagne C., Langslet G., McCrindle B.W., Wiegman A. et al. Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. J Am Coll Cardiol 2010; 55(11): 1121—1126. DOI: 10.1016/j.jacc.2009.10.042Avis H.J., Hutten B.A., Gagne C., Langslet G., McCrindle B.W., Wiegman A. et al. Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. J Am Coll Cardiol 2010; 55(11): 1121—1126. DOI: 10.1016/j.jacc.2009.10.042Raitakari O.T., Juonala M., Kahonen M., Taittonen L., Lai-tinen T., Maki-Torkko N. et al. Cardiovascular risk factors in children and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290: 2277—2283. DOI: 10.1001/jama.290.17.2277Raitakari O.T., Juonala M., Kahonen M., Taittonen L., Lai-tinen T., Maki-Torkko N. et al. Cardiovascular risk factors in children and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290: 2277—2283. DOI: 10.1001/jama.290.17.2277Kusters D.M., Wiegman A., Kastelein J.J.P., Hutten B.A. Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia. Circulation Res 2013; 114(2): 307— 310. DOI: 10.1161/circresaha.114.301430Kusters D.M., Wiegman A., Kastelein J.J.P., Hutten B.A. Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia. Circulation Res 2013; 114(2): 307— 310. DOI: 10.1161/circresaha.114.301430Braamskamp M.J., Hutten B.A., Wiegman A. Early initiation of statin treatment in children with familial hypercholes-terolaemia. Curr Opin Lipidol 2015; 26(3): 236—239. DOI: 10.1097/mol.0000000000000177Braamskamp M.J., Hutten B.A., Wiegman A. Early initiation of statin treatment in children with familial hypercholes-terolaemia. Curr Opin Lipidol 2015; 26(3): 236—239. DOI: 10.1097/mol.0000000000000177De Jongh S., Lilien M.R., op’t Roodt J., Stroes E.S., Bak-ker H.D., Kastelein J.J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40(12): 2117—2121. DOI: 10.1016/s0735-1097(02)02593-7De Jongh S., Lilien M.R., op’t Roodt J., Stroes E.S., Bak-ker H.D., Kastelein J.J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40(12): 2117—2121. DOI: 10.1016/s0735-1097(02)02593-7Harada-Shiba M., Ohta T., Ohtake A., Ogura M., Dobashi K., Nohara A. et al. Guidance for Pediatric Familial Hypercholesterolemia 2017. J Atheroscler Thromb 2018; 25(6): 539—553. DOI: 10.5551/jat.14621Harada-Shiba M., Ohta T., Ohtake A., Ogura M., Dobashi K., Nohara A. et al. Guidance for Pediatric Familial Hypercholesterolemia 2017. J Atheroscler Thromb 2018; 25(6): 539—553. DOI: 10.5551/jat.14621Watts G., Gidding S., Wierzbicki A., Toth P. P., Alonso R., Brown W.V. et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Inter J Cardiol 2014; 171: 309—325. DOI: 1016/j.ijcard.2013.11.025Watts G., Gidding S., Wierzbicki A., Toth P. P., Alonso R., Brown W.V. et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Inter J Cardiol 2014; 171: 309—325. DOI: 1016/j.ijcard.2013.11.025Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G. et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S1—8. DOI: 10.1016/j.jacl.2011.03.001Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G. et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S1—8. DOI: 10.1016/j.jacl.2011.03.001Descamps O.S., Tenoutasse S., Stephenne X., Gies I., Beau-loye V., Lebrethon M.C. et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218(2): 272—280. DOI: 10.1016/j.atherosclerosis.2011.06.016Descamps O.S., Tenoutasse S., Stephenne X., Gies I., Beau-loye V., Lebrethon M.C. et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218(2): 272—280. DOI: 10.1016/j.atherosclerosis.2011.06.016Kennedy M.J., Jellerson K.D., Snow M.Z., Zacchetti M.L. Challenges in the pharmacologic management of obesity and secondary dyslipidemia in childrenand adolescents. Pediatr Drugs 2013; 15: 335—342. DOI: 10.1007/s40272-013-0028-2Kennedy M.J., Jellerson K.D., Snow M.Z., Zacchetti M.L. Challenges in the pharmacologic management of obesity and secondary dyslipidemia in childrenand adolescents. Pediatr Drugs 2013; 15: 335—342. DOI: 10.1007/s40272-013-0028-2De Ferranti S., Ludwig D.S. Storm over statins—the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008; 359(13): 1309—1312. DOI: 10.1056/NEJMp0805953De Ferranti S., Ludwig D.S. Storm over statins—the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008; 359(13): 1309—1312. DOI: 10.1056/NEJMp0805953Wagner J.B. Children Are Not Small Adults: Specific Findings in Statin Exposure and Response in a Growing Population. Clin Pharmacol Therap 2019; 106(2): 278—280. DOI: 10.1002/cpt.1431Wagner J.B. Children Are Not Small Adults: Specific Findings in Statin Exposure and Response in a Growing Population. Clin Pharmacol Therap 2019; 106(2): 278—280. DOI: 10.1002/cpt.1431Thompson P.D. Statin-Associated Myopathy. JAMA 2003; 289: 1681. DOI: 10.1001/jama.289.13.1681Thompson P.D. Statin-Associated Myopathy. JAMA 2003; 289: 1681. DOI: 10.1001/jama.289.13.1681Avis H.J., Vissers M.N., Stein E.A. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803—1810. DOI: 10.1161/ATVBAHA.107.145151Avis H.J., Vissers M.N., Stein E.A. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803—1810. DOI: 10.1161/ATVBAHA.107.145151Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casu-la M., Badimon L. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111—188. DOI: 10.1093/eu-rheartj/ehz455Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casu-la M., Badimon L. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111—188. DOI: 10.1093/eu-rheartj/ehz455Desai N.K., Mendelson M.M., Baker A., Ryan H.H., Griggs S., Boghani M. et al. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia. JPGN 2019; 68; 2: 175—181. DOI: 10.1097/MPG.0000000000002174Desai N.K., Mendelson M.M., Baker A., Ryan H.H., Griggs S., Boghani M. et al. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia. JPGN 2019; 68; 2: 175—181. DOI: 10.1097/MPG.0000000000002174Vuorio A., Kuoppala J., Kovanen P.T., Humphries S. E., Tonstad S., Wiegman A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2019; 2019(11): CD006401. DOI: 10.1002/14651858.CD006401.pub5Vuorio A., Kuoppala J., Kovanen P.T., Humphries S. E., Tonstad S., Wiegman A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2019; 2019(11): CD006401. DOI: 10.1002/14651858.CD006401.pub5Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425— 2437. DOI: 10.1093/eurheartj/ehv157Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425— 2437. DOI: 10.1093/eurheartj/ehv157Shafiq N., Bhasin B., Pattanaik S., Pandhi P, Venkate-shan S.P., Singh M. et al. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Therap 2007; 45: 548—555. DOI: 10.5414/CPP45548Shafiq N., Bhasin B., Pattanaik S., Pandhi P, Venkate-shan S.P., Singh M. et al. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Therap 2007; 45: 548—555. DOI: 10.5414/CPP45548Carreau V., Girardet J.P., Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia. Efficacy and tolerability. Pediatr Drugs.2011; 13: 267-275. DOI: 10.2165/11591650-000000000-00000Carreau V., Girardet J.P., Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia. Efficacy and tolerability. Pediatr Drugs.2011; 13: 267-275. DOI: 10.2165/11591650-000000000-00000Besseling J., Kastelein J.J., Defesche J.C., Hutten B.A., Ho-vingh G.K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015; 313(10): 358-361. DOI: 10.1001/jama.2015.1206Besseling J., Kastelein J.J., Defesche J.C., Hutten B.A., Ho-vingh G.K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015; 313(10): 358-361. DOI: 10.1001/jama.2015.1206Kusters D.M., Wiegman A., Kastelein J.J.P., Hutten B.A. Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia. Circulation Res 2013, 114(2): 307-310. DOI: 10.1161/circresaha.114.301430Kusters D.M., Wiegman A., Kastelein J.J.P., Hutten B.A. Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia. Circulation Res 2013, 114(2): 307-310. DOI: 10.1161/circresaha.114.301430Joyce N., Zachariah J.P., Eaton C.B., Trivedi A.N., Welle-nius G.A. Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents. Acad Pediatr 2017; 17(5): 515— 522. DOI: 10.1016/j.acap.2017.02.006Joyce N., Zachariah J.P., Eaton C.B., Trivedi A.N., Welle-nius G.A. Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents. Acad Pediatr 2017; 17(5): 515— 522. DOI: 10.1016/j.acap.2017.02.006Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtc-her K.K., Blumenthal R.S. et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25): e1082-e1143. DOI: 10.1161/CIR.0000000000000625Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtc-her K.K., Blumenthal R.S. et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25): e1082-e1143. DOI: 10.1161/CIR.0000000000000625Ramaswami U., Futema M., Bogsrud M.P., Holven K.B., Roeters van Lennep J., Wiegman A. et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 2020; 292: 178-187. DOI: 10.1016/j.atherosclerosis.2019.11.012Ramaswami U., Futema M., Bogsrud M.P., Holven K.B., Roeters van Lennep J., Wiegman A. et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 2020; 292: 178-187. DOI: 10.1016/j.atherosclerosis.2019.11.012Клинические рекомендации. Семейная гиперхолестеринемия. 2018 г. https://noatero.ru/sites/default/files/proekt_klinicheskie_rekomendacii_sghs_mz_rf_18.01.pdf.Clinical guidelines. Familial hypercholesterolemia. 2018 (in Russ.)https://noatero.ru/sites/default/files/proekt_klinicheskie_rekomendacii_sghs_mz_rf_18.01.pdf.

The authors declare that there are no conflicts of interest present.